Alectos Supports NSERC Funding for Prof. A.J. Bennet at SFU

­

Alectos Supports NSERC Funding for Prof. A.J. Bennet at SFU

Feb 11, 2016 – Alectos today announced its support for NSERC funding for the group of Prof. A.J. Bennet at Simon Fraser University, Department of Chemistry, in a project titled “Fundamental Studies on the Biochemical Mechanism of Chemical Chaperoning of Glucocerebrosidase”.

Parkinson’s disease is a worldwide health problem that has been linked to deficiencies in an enzyme called
glucocerebrosidase (GCase). This enzyme plays a critical role in the body by breaking down a particular large molecule
into two smaller, more easily metabolized components, a sugar (glucose) and a fat (ceramide). Without a
properly functioning glucocerebrosidase, these large molecules are not degraded in a normal manner. Genetic
mutations associated with glucocerebrosidase often result in an unstable enzyme structure that is easily
damaged in the intracellular environment. In the case of Parkinson’s disease, loss of function of this enzyme
may contribute to disease progression.

Current treatments for Parkinson’s disease address disease symptoms but do not affect disease progression.
New disease-modifying therapies are therefore urgently required. The collaboration between Alectos
Therapeutics and the Bennet group at Simon Fraser University will address basic scientific questions around
the finely tuned activities that enable this important enzyme to function properly. The project will be guided by
the Bennet group’s ingenuity in the area of enzyme biochemistry and will provide unique opportunities for
these university researchers to work alongside industry scientists at Alectos Therapeutics. Anticipated scientific
advances made by this university – industry partnership include the design of small molecules that strengthen
the enzyme’s structure, helping to increase its robustness and hence its ability to function properly. Not only
will this work broaden our understanding of the molecular details inherent in enzyme function, but this
knowledge will also drive the downstream design of new strategies to prevent and treat Parkinson’s disease.